All of us want good-looking skin. Acne is the biggest obstacle in our effort. There are other skin problems that look like acne but are not acne. Milia is one of them. Milia are white spots on the face that can form at any age. Milia look like white pearls and most of us confuse them with whiteheads of acne. They are not whiteheads. So the treatment is different. Common acne treatment will not help remove milia but create more skin problems. Find out the difference between milia and whiteheads for a good-looking face.
Acne- what are whiteheads: whiteheads form when the dead skin cells, white blood cells, bacteria P.Acnes and sebum block the opening of the sebaceous glands. The gland has a closed mouth and this comedone is called acne. This acne troubles us because if it gets further infected, it can create scarring and spoil the facial skin forever.
Mila- milia is the accumulation of dead skin cells that is not able to get out of the skin. Milia has no infection like whiteheads and no bacteria or pus. Milia has no sebum in its formation. Our skin sheds dead skin cells everyday. Sometimes, when these cells cannot be shed out from the skin, they accumulate and form miila. When you extract a milia from the skin, you will only see white mass. They are dead skin cells.
Acne: Rambazole Can Be A Good Medication Against Acne In Future
A study with Rambazole, a novel retinoic acid metabolism-blocking agent (RAMBA), determined that 94 per cent of subjects -with moderate-to-severe acne treated with 1 mg of oral Rambazole once daily for 12 consecutive weeks- experienced reduction in total acne lesion count of more than 50 per cent and 35 per cent were considered "cleared or almost cleared.
This study points to the production of this medication on future, since Barrier Therapeutics, Inc. reported positive Phase 2a data for its oral formulation of Rambazole (TM) in the treatment of moderate to severe acne and positive biological activity data for its topical formulation of this product.
Experts explain that a subject must have had more than 90 per cent reduction in total lesion count to be considered “cleared or almost cleared”. According to their report, inflammatory and non-inflammatory lesions responded equally well to treatment. There were no serious effects related to the treatment with this new component. Only some patients of the group in study experienced dryness of skin and lips as non-serious side effects.
Geert Cauwenbergh, Ph.D., Chairman and Chief Executive Officer of Barrier Therapeutics, Inc. explained that “these positive Phase 2a results indicate that oral Rambazole is active in moderate to severe inflammatory acne, and that depending on the outcome of future, full scale clinical trials, this drug may one day fill the need for safe and effective oral treatments for moderate and severe acne. These results further build on our previously announced promising clinical data for oral Rambazole for psoriasis”.
This study points to the production of this medication on future, since Barrier Therapeutics, Inc. reported positive Phase 2a data for its oral formulation of Rambazole (TM) in the treatment of moderate to severe acne and positive biological activity data for its topical formulation of this product.
Experts explain that a subject must have had more than 90 per cent reduction in total lesion count to be considered “cleared or almost cleared”. According to their report, inflammatory and non-inflammatory lesions responded equally well to treatment. There were no serious effects related to the treatment with this new component. Only some patients of the group in study experienced dryness of skin and lips as non-serious side effects.
Geert Cauwenbergh, Ph.D., Chairman and Chief Executive Officer of Barrier Therapeutics, Inc. explained that “these positive Phase 2a results indicate that oral Rambazole is active in moderate to severe inflammatory acne, and that depending on the outcome of future, full scale clinical trials, this drug may one day fill the need for safe and effective oral treatments for moderate and severe acne. These results further build on our previously announced promising clinical data for oral Rambazole for psoriasis”.
Subscribe to:
Posts (Atom)